My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
Recent NDRA News
- ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents • Business Wire • 05/02/2024 12:00:00 PM
- ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • Business Wire • 03/28/2024 08:05:00 PM
- ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024 • Business Wire • 03/21/2024 12:00:00 PM
- ENDRA Life Sciences Installs First TAEUS System in the UK • Business Wire • 02/27/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:00:45 PM
- New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System • Business Wire • 02/21/2024 01:00:00 PM
- ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe • Business Wire • 02/14/2024 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/29/2023 10:07:32 PM
- ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology • Business Wire • 11/29/2023 01:00:00 PM
- ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference • Business Wire • 11/27/2023 01:00:00 PM
- ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update • Business Wire • 11/14/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:02:23 PM
- ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents • Business Wire • 11/08/2023 01:00:00 PM
- ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023 • Business Wire • 11/07/2023 09:05:00 PM
- ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023 • Business Wire • 11/06/2023 01:00:00 PM
- Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023 • Business Wire • 09/07/2023 12:00:00 PM
- ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA • Business Wire • 08/30/2023 12:00:00 PM
- ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents • Business Wire • 08/23/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:45:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:13:52 PM
- ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update • Business Wire • 08/14/2023 08:05:00 PM
- ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA • Business Wire • 08/14/2023 05:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 12:01:23 PM
- ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023 • Business Wire • 08/01/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM